98%
921
2 minutes
20
Key Points: The association between aspirin use and risk of the first cardiovascular event was NS in patients with CKD. Compared with nonusers, aspirin users had an increased risk of significant bleeding events. Aspirin prescription for the primary prevention of cardiovascular disease in patients with CKD needs careful consideration.
Background: Despite the high cardiovascular risk in patients with CKD, the role of aspirin in primary prevention remains unclear. This study aimed to investigate the association between aspirin initiation in adults with CKD without prior cardiovascular disease (CVD) and the first cardiovascular and bleeding events using Korean nationwide cohort data.
Methods: Among individuals aged 40–79 years with an eGFR between 15 and 59 ml/min per 1.73 m who underwent routine health examinations between 2011 and 2016, 15,861 individuals who were newly prescribed aspirin at a dose of 100 mg/d were matched with 79,305 aspirin non-users by propensity score matching. The primary efficacy outcome was a composite of nonfatal atherosclerotic CVD or cardiovascular death. The primary safety outcome was hospitalization due to intracranial or gastrointestinal bleeding.
Results: During a mean follow-up of 6.9±2.9 years, the incidence rates for the primary efficacy outcome in aspirin users and nonusers were 8.0 and 9.0 per 1000 person-years, respectively. Aspirin therapy initiation was not associated with the primary efficacy outcome (hazard ratio, 0.93; 95% confidence intervals, 0.86 to 1.04). However, the primary safety outcome of major bleeding was more frequent in aspirin users than in nonusers (6.7 versus 4.7 per 1000 person-years). The hazard ratio for this outcome in aspirin users versus nonusers was 1.45 (95% confidence intervals, 1.32 to 1.59).
Conclusions: No association was observed between aspirin use and the risk of nonfatal atherosclerotic CVD or cardiovascular death in patients with CKD stages G3 and G4 without prior CVD. Aspirin use was associated with higher risk of major bleeding.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905995 | PMC |
http://dx.doi.org/10.2215/CJN.0000000619 | DOI Listing |
Nephrol Dial Transplant
September 2025
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: We investigated circulating protein profiles and molecular pathways among various chronic kidney disease (CKD) etiologies to study its underlying molecular heterogeneity.
Methods: We conducted a proteomic biomarker analysis in the DAPA-CKD trial recruiting adults with and without type 2 diabetes with an eGFR of 25 to 75 mL/min/1.73m2 and a UACR of 200 to 5000 mg/g.
Cell Mol Biol (Noisy-le-grand)
September 2025
University Sousse, Faculty of Medicine "Ibn El-Jazzar", Department of Medical Genetics, Sousse, Tunisia.
The global epidemic of overweight and obesity is closely linked to the development of chronic kidney disease (CKD), with extremely obese individuals facing a particularly high risk. This study aimed to assess the relationship between lipid profile levels, SIRT1 expression, and RNA-34a-5P in the regulation of blood lipid levels among severely obese individuals with renal diseases. Conducted over six months in three specialized hospitals, the study included 100 participants divided into two groups: 50 obese individuals with renal diseases and 50 obese controls without renal problems.
View Article and Find Full Text PDFIr J Med Sci
September 2025
Sri Venkateswara Institute of Medical Sciences, Tirupati, India.
Introduction: Information on tertiary hyperparathyroidism (THPTH) among chronic kidney disease (CKD) patients on haemodialysis in developing countries such as India is limited, and the mortality among them remains a query.
Materials And Methods: This was a prospective cohort study conducted in at a tertiary care centre from June 2017 to June 2022. The index of suspicion for tertiary hyperparathyroidism was when investigations revealed high serum calcium and high alkaline phosphatase along with new onset of body aches, joint pains, and difficulty in walking.
Int Urol Nephrol
September 2025
Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan.
J Nephrol
September 2025
Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Nishi-cho 36-1, Yonago, Tottori, 683-8504, Japan.
Background: Chronic kidney disease (CKD) is a public health concern; kidney size correlates with kidney function, except in diabetic kidney disease (DKD), where the kidney enlarges, limiting morphological measurement applications in CKD management. However, cortical size changes in DKD along with CKD progression remain understudied. We investigated kidney morphology alterations in patients with and without diabetes and established a regression equation for kidney function incorporating morphological alterations.
View Article and Find Full Text PDF